Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05292339 · ClinicalTrials.gov registry record · Phase 4
Ketorolac in Upper Extremity Tendinopathy and Arthropathy
A Phase 4 study of Osteoarthritis and Tendinopathy, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 160
- Enrollment target
- 4
- Study locations
NCT05292339 is a Phase 4 study of Osteoarthritis and Tendinopathy that is actively recruiting participants, run by Emory University. The registered enrollment target is 160 participants, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (80% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT05292339, a Phase 4 study of Osteoarthritis and Tendinopathy, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 160 participants
- Enrollment target
- 4
- Study locations
Study Summary
Osteoarthritis (OA) and inflammatory conditions of the tendons and joints of the shoulder, elbow, hand, and wrist are common yet disabling diseases. Standard management utilizes conservative measures to minimize pain and improve function. Conservative pharmacological management commonly includes corticosteroid and ketorolac injections which have been well investigated as a modality of pain control and improved function in large joint OA. However, fewer studies yielding mixed results on the duration of symptomatic relief exist for arthropathy and tendinopathy of these joints. The goal of this study is to evaluate the efficacy of ketorolac and triamcinolone injections for common shoulder, elbow, wrist, and hand tendinopathy or arthropathy. Participants will be blinded to the treatment received. The duration of an individual participant's participation in this study is 24 weeks. During this time period, patients will be asked to return to the clinic for an in-person follow-up 6 weeks after the injection with either ketorolac or triamcinolone) in order to assess participants' outcomes. All work related to this project will take place at the Emory Sports Medicine Complex, Emory Executive Park, Emory Musculoskeletal Institute, the Emory University Orthopaedic and Spine Hospital, and the Emory Saint Joseph's Hospital. This study will add to existing knowledge by providing further insight into how wrist arthropathy should be most optimally and conservatively managed.
Conditions Studied
Interventions
- DRUG Triamcinolone injection to the shoulder, elbow, wrist, or hand
- DRUG Ketorolac injection to the shoulder, elbow, wrist, or hand
Study Locations (4)
Georgia
- Emory Saint Joseph's Hospital - Atlanta
- Emory University Orthopaedic and Spine Center - Atlanta
- 12 Executive Park Drive - Atlanta
- Emory University Orthopaedic and Spine Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2023-01-31 |
| Est. Completion | 2027-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05292339
The ClinicalTrials.gov registry entry for NCT05292339 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (80% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Triamcinolone injection to the shoulder, elbow, wrist, or hand is the first listed.
NCT05292339 reports 4 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05292339 about?
NCT05292339 is a clinical study titled "Ketorolac in Upper Extremity Tendinopathy and Arthropathy". Osteoarthritis (OA) and inflammatory conditions of the tendons and joints of the shoulder, elbow, hand, and wrist are common yet disabling diseases. Standard management utilizes conservative measures to minimize pain and improve function. Conservative pharmacological management commonly includes cor...
What is the current status of trial NCT05292339?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2023-01-31. Estimated completion is 2027-07.
What conditions does trial NCT05292339 study?
This clinical trial studies the following conditions: Osteoarthritis, Tendinopathy, Arthropathy.
What interventions are being tested in trial NCT05292339?
The interventions under investigation include: Triamcinolone injection to the shoulder, elbow, wrist, or hand (DRUG), Ketorolac injection to the shoulder, elbow, wrist, or hand (DRUG).
Who is sponsoring clinical trial NCT05292339?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05292339 being conducted?
This trial has 4 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic Oral Glucocorticoids for the Treatment of Acute Osteoarthritis Pain in the Emergency Department
RECRUITING · Phase 4
-
Preoperative Correction of Vitamin D Deficiency in Total Joint Arthroplasty (TJA)
ACTIVE NOT RECRUITING · Phase 4
-
Duloxetine in Osteoarthritis (OA) Pain
COMPLETED · Phase 4
-
TREAD-20: Trial of Hyalgan Three Injection-Regimen for the Treatment of Knee Pain Due to Osteoarthritis
COMPLETED · Phase 4
-
Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement
COMPLETED · Phase 4
-
The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.